Skip Navigation



Japanese Journal of Clinical Oncology Advance Access published online on August 22, 2006
Japanese Journal of Clinical Oncology, doi:10.1093/jjco/hyl086
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
36/10/613    most recent
hyl086v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Rastogi, M.
Right arrow Articles by Mehrotra, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rastogi, M.
Right arrow Articles by Mehrotra, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 Foundation for Promotion of Cancer Research
Received April 1, 2006
Accepted June 26, 2006

Original Article

Esthesioneuroblastoma Treated with Non-Craniofacial Resection Surgery Followed by Combined Chemotherapy and Radiotherapy: An Alternative Approach in Limited Resources

Madhup Rastogi 1 *, M. L. B. Bhatt 1, K. S. Chufal 2, M. Srivastava 1, M. C. Pant 1, Kirti Srivastava 1, and Sanjay Mehrotra 3

1 Department of Radiotherapy, King George's Medical University, Lucknow, Uttar Pradesh, India
2 Department of Oncology, Batra Hospital and Medical Research Center, New Delhi, India
3 Department of Medicine, King George's Medical University, Lucknow, Uttar Pradesh, India

* To whom correspondence should be addressed.
Madhup Rastogi, E-mail: drmadhup1{at}rediffmail.com


  Abstract

Background: Esthesioneuroblastoma (ENB) is a rare and aggressive malignant tumor arising from olfactory epithelium. Surgical excision in the form of craniofacial surgical resection (CFR) has shown encouraging results. The purpose of the study is to analyze the outcome of this disease when managed by non-craniofacial resection (NCFR) surgery in limited resources.

Methods: Between October 1998 and January 2004, eight patients with ENB were treated in the Department of Radiotherapy at KGMU, Lucknow. None of these eight patients underwent CFR surgery. All patients received six cycles of vincristine, adriamycin and cyclophosphamide (VAC) based chemotherapy followed by radiotherapy.

Results: All the patients registered during this period had undergone operative procedures in the form of NCFR surgery except two. Complete response was present in five (62.5%) patients and three (37.5%) patients had partial response. Locoregional relapse-free survival at 3 years was 62.5% and median survival time was 38 months. Disease-free survival and overall survival at 3 years was 72.9 and 71.4%, respectively, and median disease-free survival time was 43 months, while mean overall survival time was 40.7 months as median overall survival time was not reached.

Conclusion: Patients in developing countries often present with advanced stages and because of non-availability of technical advances and surgical expertise one tends to approach these patients with palliative intent. Most of the patients in our series were of stage C disease (75%) and still our response rate and survival were encouraging despite the fact that surgery was not optimal. This combination chemoradiotherapy schedule can be used outside the protocol setting where resources are limited.

Keywords: esthesioneuroblastoma; craniofacial surgical resection; non-craniofacial surgical resection; chemotherapy; radiotherapy.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.